224 results on '"JI-BIN LI"'
Search Results
2. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
- Author
-
Tian-Qi Zhang, Zhi-Jun Geng, Meng-Xuan Zuo, Ji-Bin Li, Jin-Hua Huang, Zi-Lin Huang, Pei-Hong Wu, and Yang-Kui Gu
- Subjects
Medicine ,Biology (General) ,QH301-705.5 - Abstract
Abstract Hepatic arterial infusion chemotherapy (HAIC) using a combination of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promise for hepatocellular carcinoma (HCC) patients classified under Barcelona Clinic Liver Cancer (BCLC) stage C. In China, the combined therapy of camrelizumab and apatinib is now an approved first-line approach for inoperable HCC. This study (NCT04191889) evaluated the benefit of combining camrelizumab and apatinib with HAIC-FOLFOX for HCC patients in BCLC stage C. Eligible patients were given a maximum of six cycles of HAIC-FOLFOX, along with camrelizumab and apatinib, until either disease progression or intolerable toxicities emerged. The primary outcome measured was the objective response rate (ORR) based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Thirty-five patients were enrolled. Based on RECIST v1.1 criteria, the confirmed ORR stood at 77.1% (95% CI: 59.9% to 89.6%), with a disease control rate of 97.1% (95% CI: 85.1% to 99.9%). The median progression-free survival was 10.38 months (95% CI: 7.79 to 12.45). Patient quality of life had a transient deterioration within four cycles of treatment, and generally recovered thereafter. The most frequent grade ≥3 or above treatment-related adverse events included reduced lymphocyte count (37.1%) and diminished neutrophil count (34.3%). The combination of camrelizumab, apatinib, and HAIC demonstrated encouraging results and manageable safety concerns for HCC at BCLC stage C.
- Published
- 2023
- Full Text
- View/download PDF
3. Short‐term outcomes of robotic lobectomy versus video‐assisted lobectomy in patients with pulmonary neoplasms
- Author
-
Tian‐Yu Sun, Chu‐Long Xie, Zihui Tan, Ji‐Bin Li, Mu‐Zi Yang, and Hao‐Xian Yang
- Subjects
lobectomy ,lung neoplasm ,robotic surgery ,short‐term outcome ,video‐assisted thoracic surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background To explore whether robotic lobectomy (RL) is superior to video‐assisted lobectomy (VAL) in terms of short‐term outcomes in patients with pulmonary neoplasms. Methods From January 30, 2019 to February 28, 2022, a series of consecutive minimally invasive lobectomies were performed for patients with pulmonary neoplasms. Perioperative outcomes such as operation time, blood loss, dissected lymph nodes (LNs), surgical complications, postoperative pain control, length of postoperative stay in hospital, and total cost of hospitalization were compared. Results A total of 336 cases including 173 RLs and 163 VALs were enrolled. Baseline characteristics were comparable between groups. RLs were associated with shorter operation time (median [interquadrant range, IQR], 107 min [90–130] vs. 120 min [100–149], p
- Published
- 2023
- Full Text
- View/download PDF
4. Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA–IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trialResearch in context
- Author
-
Dong-Hua Luo, Xiao-Yun Li, Shan-Shan Guo, Wan-Ping Guo, Li-Ting Liu, Hao-Yuan Mo, Ling Guo, Xiao-Fei Lv, Li-Zhi Liu, Ji-Bin Li, Qing Liu, Pan Wang, Xue-Song Sun, Sai-Lan Liu, Qiu-Yan Chen, Lin-Quan Tang, and Hai-Qiang Mai
- Subjects
Nasopharyngeal carcinoma ,Children and adolescents ,Chemoradiotherapy ,Induction chemotherapy ,Survival ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Previous studies demonstrated that induction chemotherapy (IC) followed by de-escalated chemoradiotherapy adapted to tumor response was effective in treating childhood nasopharyngeal carcinoma (NPC), but the toxicity profile of this treatment strategy, and whether childhood patients with advanced stages can obtain enough benefits from it requires further investigation. Methods: We conducted a single-center phase II trial (NCT03020329). All participants received 3 cycles of paclitaxel liposome, cisplatin and 5-fluorouracil (TPF)-based IC. Patients who showed complete or partial response received de-escalated radiotherapy of 60 Gy with 3 cycles of concurrent cisplatin, and those who showed stable or progressive disease received standard-dose radiotherapy of 70 Gy with concurrent cisplatin. The primary endpoint was the complete response (CR) rate at the end of concurrent chemoradiotherapy (CCRT). Findings: From November 2016 to March 2021, 44 patients were recruited in the cohort. The CR rate was 80% (35/44, 95% CI, 65–90) of the whole cohort. All patients achieved CR 3 months after CCRT. By the last follow-up, the 3-year progression-free survival and overall survival were 91% (95% CI, 82–99) and 100% respectively. Dry mouth was the most common late toxicity, with an incidence of 41% (18/44), followed by skin fibrosis and hearing impairment. No patient suffered from severe late toxicity and growth retardation. Interpretation: Our results proved the efficacy and safety of TPF regimen followed by de-escalated radiotherapy with concurrent cisplatin in treating stage IVa-b childhood NPC patients. Funding: A full list of funding bodies that contributed to this study can be found in the Acknowledgements section.
- Published
- 2023
- Full Text
- View/download PDF
5. P1140: COMBINATION ANTI-PD1 ANTIBODY AND RITUXIMAB FOLLOWED BY R-CHOP FOR NEWLY DIAGNOSED DLBCL IN ELDERLY PATIENTS: ANALYSIS OF THE PHASE II TREND TRIAL
- Author
-
Yan Gao, Xue-Ping LI, Xiao-Xiao Wang, Bing Bai, Xuan-Ye Zhang, Su-Xia Lin, Yan-Xia He, LI-Qin Ping, Cheng Huang, Ji-Bin LI, Jia-Ling Zhuang, and Hui-Qiang Huang
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
6. Factors associated with adherence to colonoscopy among individuals who were positive in the preliminary screening for colorectal neoplasms
- Author
-
Ji‐Bin Li, Keng‐Jian Ke, Wei‐Li Zhang, Ling‐Yan Wang, Yan‐Ping Wu, Fan Weng, Huan Tian, Zhi‐Yu Qiu, Yin Li, Shi‐Yong Lin, Mei‐Xian Ye, Qing‐Jian Ou, Cheng‐Hua Gong, Zhen‐Hai Lu, Zhi‐Zhong Pan, De‐Sen Wan, Jian‐Hong Peng, and Yu‐Jing Fang
- Subjects
adherence to colonoscopy ,colorectal cancer screening ,fecal immunochemical test ,high‐risk factor questionnaire ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objectives This study aimed to investigate the potential factors associated with adherence to colonoscopy among participants who were preliminarily screened positive in a community‐based colorectal cancer screening program in China. Methods This study analyzed data from 1219 out of 6971 community residents who were identified as positive cases by the well‐validated high‐risk factor questionnaire (HRFQ) or fecal immunochemical test (FIT) in the preliminary screening stage for colorectal neoplasms. Patients showing adherence to colonoscopy were defined as those who received positive results in a preliminary screening for colorectal neoplasms and later received a colonoscopy examination as required. The associations of social‐demographic factors, lifestyle behaviors, history of diabetes, body mass index (BMI), and risk factors in the HRFQ with adherence to colonoscopy were evaluated using logistic regression models. Results Among 1219 participants who preliminarily screened positive, the top five risk factors reported by the participants were chronic constipation (25.9%), hematochezia (23.5%), family history of CRC in first‐degree relatives (22.1%), chronic diarrhea (21.8%), and history of polyps (16.6%). Around 14.2% of participants who preliminarily screened positive reported three or more risk factors, and the proportion was 26.2% among participants who were positive according to both HRFQ and FIT. Among all participants who were preliminarily screened positive, the multivariable results showed that those who were married (OR = 1.58, 95% CI: 1.12, 2.25, p = 0.01), had chronic diarrhea (OR = 1.34, 95% CI: 1.00, 1.78, p = 0.047), and had a positive FIT (OR = 1.60, 95% CI: 1.21, 2.10, p
- Published
- 2022
- Full Text
- View/download PDF
7. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society
- Author
-
Ji-Bin Li, Zhuo-Chen Lin, Martin C. S. Wong, Harry H. X. Wang, Mengmeng Li, and Su Li
- Subjects
Cost-effectiveness ,Quality-adjusted life years ,Capecitabine maintenance therapy ,Early-stage triple-negative breast cancer ,Medicine - Abstract
Abstract Background Capecitabine maintenance therapy is safe and efficacious for early-stage triple-negative breast cancer (TNBC) patients, but the cost-effectiveness of its long-term use has not been investigated. Here, we evaluated the cost-effectiveness of capecitabine maintenance therapy, compared with routine follow-up, in early-stage TNBC patients after standard treatment from a perspective of Chinese society. Methods A three-state Markov model based on the data from the SYSUCC-001 trial was constructed to estimate the cost-effectiveness of capecitabine maintenance therapy in a month cycle over a period of 30-year time horizon. A 5% annual discount rate was set for all costs and benefits. One-way and probabilistic sensitivity analyses were performed to explore the model uncertainties. The main outcomes include quality-adjusted life years (QALYs), incremental cost-effectiveness ratio (ICER), and the number needed to treat (NNT) to prevent one additional event. Results Compared with routine follow-up, 1-year capecitabine maintenance therapy yielded an additional 1.29 quality-adjusted life years (QALYs) at an additional cost of $3391.70, with an ICER of $2630.53 (95% CI: $1159.81–$5090.12) per QALY gained. The ICER was considerably lower than the recommended willingness-to-pay (WTP) threshold (i.e., $28,130.00 per QALY). The results were sensitive to the discount rate, drug cost, and treatment cost after relapse. Further, the NNT to prevent one additional relapse case was 29.2 (95% CI: 13.2–196.6), 16.7 (95% CI: 8.4–111.6), and 12.0 (95% CI: 5.7–82.6) at 1, 2, and 5 years, respectively. Conclusions One-year capecitabine maintenance therapy for early-stage TNBC after standard treatment, compared with routine follow-up, was found to be highly cost-effective with promising clinical benefits and acceptable increased costs. Real-world studies are warranted to validate our findings in the future.
- Published
- 2022
- Full Text
- View/download PDF
8. Station 3A lymph node dissection does not improve long‐term survival in right‐side operable non‐small‐cell lung cancer patients: A propensity score matching study
- Author
-
Mu‐Zi Yang, Zi‐Hui Tan, Ji‐Bin Li, Hao Long, Jian‐Hua Fu, Lan‐Jun Zhang, Peng Lin, Xue Hou, and Hao‐Xian Yang
- Subjects
mediastinal lymph node dissection ,non‐small‐cell lung cancer ,prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background To investigate the impact of station 3A lymph node dissection (LND) on overall survival (OS) and disease‐free survival (DFS) in completely resected right‐side non‐small‐cell lung cancer (NSCLC) patients. Methods A total of 1661 cases with completely resected right‐side NSCLC were included. Propensity score matching (PSM) was performed to minimize selection bias, and a logistic regression model was conducted to investigate the risk factors associated with station 3A lymph node metastasis (LNM). The Kaplan–Meier method and Cox proportional hazards model were used to evaluate the impact of station 3A LND on survival. Results For the entire cohort, 503 patients (30.3%) underwent station 3A LND. Of those, 11.3% (57/503) presented station 3A LNM. Univariate and multivariate logistic analyses showed that station 10 LNM, tumor location, and the number of resected lymph nodes were independent risk factors associated with station 3A LNM. Before PSM, patients with station 3A LND had worse 5‐year OS (p = 0.002) and DFS (p = 0.011), and more drainage on postoperative day 1 (p = 0.041) than those without. After PSM, however, station 3A LND was not associated with the 5‐year OS (65.7% vs. 63.6%, p = 0.432) or DFS (57.4% vs. 56.0%, p = 0.437). The multivariate analysis further confirmed that station 3A LND was not a prognostic factor (OS, p = 0.361; DFS, p = 0.447). Conclusions Station 3A LND could not improve long‐term outcomes and it was unnecessary to dissect station 3A lymph nodes during surgery of right‐side NSCLC.
- Published
- 2022
- Full Text
- View/download PDF
9. Concurrent chemotherapy using taxane plus cisplatin cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy
- Author
-
Ya-Ni Zhang, Yu-Pei Chen, Ji-Bin Li, Tai-Xiang Lu, Fei Han, and Chun-Yan Chen
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Detectable Epstein–Barr virus (EBV) DNA levels and unsatisfactory tumor response to induction chemotherapy (IC) could be used to guide the risk-adapted treatment strategy of locoregionally advanced nasopharyngeal carcinoma (LANPC) before concurrent chemoradiotherapy. We aim to compare the efficacy and safety of concurrent chemotherapy using taxane plus cisplatin [double-agent concurrent chemotherapy (DACC) group] with those of cisplatin alone [single-agent concurrent chemotherapy (SACC) group] in high-risk LANPC. Methods: Overall, 197 LANPC patients with detectable EBV DNA or stable disease (SD) after IC were retrospectively included. Potential confounders between the DACC and SACC groups were adjusted by propensity score matching. Short-term efficacy and long-term survival were assessed in the two groups. Results: Although the objective response rate of the DACC group was marginally higher than that of the SACC group, the difference was not significant (92.7% versus 85.3%, p = 0.38). Concerning long-term survival, DACC did not show superiority to SACC after patient matching: 3-year progression-free survival: 87.8% versus 81.7%, p = 0.80; overall survival: 97.6% versus 97.3%, p = 0.48; distant metastasis-free survival: 87.8% versus 90.5%, p = 0.64, and; locoregional relapse-free survival: 92.3% versus 86.9%, p = 0.77. The incidence of grade 1–4 hematological toxicities was significantly higher in the DACC group. Conclusion: Due to the small sample size, we do not have sufficient evidence that concurrent chemotherapy using taxane plus cisplatin provides additional survival benefits in LANPC patients with an unfavorable response (detectable EBV DNA levels or SD) after IC. But concurrent taxane and cisplatin chemotherapy is associated with a higher rate of hematologic adverse events. Further clinical trials will be required to establish evidence and identify more effective treatment modalities for high-risk LANPC patients.
- Published
- 2023
- Full Text
- View/download PDF
10. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials
- Author
-
Hui-Zhen Wu, Yuan Cheng, Ding Yu, Ji-Bin Li, Yun-Fa Jiang, and Zhong-Ning Zhu
- Subjects
nifedipine ,hydralazine ,labetalol ,severe hypertension ,pregnancy ,network meta-analysis ,Gynecology and obstetrics ,RG1-991 - Abstract
Objectives This network meta-analysis aimed to compare the efficacy and safety of intravenous (IV) hydralazine, oral nifedipine, and IV labetalol with different dosage regimens in the treatment of severe hypertension during pregnancy. Methods A comprehensive literature search was performed on PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) exploring the effects of hydralazine, nifedipine, and labetalol in the treatment of severe hypertension during pregnancy. Results A total of 21 RCTs with 2183 patients comparing 7 regimens (oral nifedipine 50,60,90 mg; hydralazine 15,25 mg; and labetalol 220,300 mg) were identified. Compared with IV labetalol 300 mg, nifedipine 50,60, and 90 mg significantly improved the successful treatment rate of severe hypertension during pregnancy, nifedipine 50 and 90 mg and IV hydralazine 25 mg required significantly fewer doses to achieve target blood pressure (BP), and nifedipine 50 mg took significantly shorter time to achieve target BP. Subgroup analysis showed that only nifedipine 50 mg tablets, not capsules, required a significantly shorter time and fewer doses to achieve target BP than IV labetalol 300 mg. Moreover, nifedipine 60,90 mg showed superior effectiveness than IV hydralazine 15,25 mg in the successful treatment rate of severe hypertension during pregnancy. SUCRA analysis suggested that nifedipine 50,60,90 mg as the better regimens with the lower rates of overall ADR and neonatal complications. Conclusion These findings demonstrated the superiority of oral nifedipine 50,60,90 mg, especially oral nifedipine 50 mg tablets, in the treatment of severe hypertension during pregnancy than IV labetalol 300 mg, while oral nifedipine 60,90 mg also showed superiority in the successful treatment rate of severe hypertension during pregnancy than IV hydralazine 15,25 mg. However, the limitations of the underlying data indicate that future large-scale and rigorous RCTs are needed to confirm such findings.
- Published
- 2022
- Full Text
- View/download PDF
11. Factors associated with positive predictive value of preliminary screening in a two-step screening strategy for colorectal neoplasms in China
- Author
-
Ji-Bin Li, Zhi-Yu Qiu, Yu-Xiang Deng, Yin Li, Zhuo-Chen Lin, Yan-Ping Wu, Fan Weng, Huan Tian, Qing-Jian Ou, Cheng-Hua Gong, Zhi-Zhong Pan, De-Sen Wan, Jian-Hong Peng, and Yu-Jing Fang
- Subjects
Positive predictive value ,Preliminary screening ,Screening algorithm ,Colorectal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The positive predictive value (PPV) of high risk factor questionnaire (HRFQ) plus fecal immunochemical test (FIT) as preliminary screening strategy for colorectal-related neoplasia is relatively low. We aim to explore independent factors associated with PPVs of HRFQ combined FIT for selecting high risk individuals for colonoscopy. Methods A total of 6971 residents were enrolled in a community-based screening program. Participants who had positive results of HRFQ and/or FIT and subsequently received colonoscopy were involved. The associations of socio-demographic factors, lifestyle behaviors, and high risk factors of colorectal cancer with PPVs of HRFQ, FIT, and their combination were evaluated by multivariable logistic regression models. Results Among 572 involved cases, 249 (43.5%) colorectal neoplasms were detected by colonoscopy, including 71 advanced adenoma (12.4%) and 9 colorectal cancer (CRC) (1.6%). The PPVs of preliminary screening were 43.5% for total colorectal neoplasms, 14.0% for advanced neoplasm, and 1.6% for CRC. Adding positive HRFQ to FIT could improve the PPV from 3.5 to 8.0% for detecting CRC. Preliminarily screened positive individuals who were males [adjusted odds ratio (AOR): 1.95, 95% CI 1.31, 2.90; p 60 years) (AOR: 1.70, 95% CI 1.17, 2.46; p = 0.005), or ex-/current smokers (AOR: 3.04, 95% CI 1.31, 7.09; p = 0.10) had higher odds of PPVs of detecting colorectal neoplasms. Conclusions Combining HRFQ and FIT could largely improve PPVs for screening advanced neoplasm and CRC. Gender and age-specific FIT cut-off values as well as initiating ages for CRC screening might be recommended to improve the accuracy and effectiveness of current screening algorithm.
- Published
- 2022
- Full Text
- View/download PDF
12. The beneficial effect of Escalated‐R‐CHOP‐21 for the treatment of diffuse large B‐cell lymphoma in elderly male patients: A propensity‐matched cohort study
- Author
-
Hai‐Xia He, Yan Gao, Bing Bai, Xiao‐Xiao Wang, Ji‐Bin Li, Cheng Huang, Jia‐Ying Mao, Li‐Qin Ping, Qi‐Xiang Rong, Yan‐Xia He, He Huang, Qing‐Qing Cai, Zhi‐Ming Li, Wen‐Qi Jiang, and Hui‐Qiang Huang
- Subjects
diffuse large B‐cell lymphoma ,elderly males ,escalated ,R‐CHOP ,rituximab ,standard ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose Some studies have indicated that using 500 mg/m2 rituximab combined with CHOP‐14 may be beneficial for elderly men but not women with diffuse large B‐cell lymphoma (DLBCL). The purpose of this study was to investigate the potential benefit of escalated doses of rituximab with CHOP‐21 as the first‐line treatment in male patients with DLBCL. Methods We performed a retrospective cohort study to analyze the survival benefit of rituximab 500 mg/m2 plus the CHOP‐21 regimen (Escalated‐R‐CHOP‐21) as the first‐line treatment compared with using rituximab 375 mg/m2 plus the CHOP‐21 regimen (Standard‐R‐CHOP‐21) in men with DLBCL. We used propensity score matching to maximize the balance of the observed covariables. The primary endpoints of this study were the progression‐free survival (PFS) rate and overall survival (OS) rate at 3 years. Results After a median follow‐up of 47 months (IQR 31–65), no significant difference in PFS and OS was found for men treated with Escalated‐R‐CHOP‐21 compared with Standard‐R‐CHOP‐21 [3‐year PFS: 69.7% versus 71.9%, p = 0.867; 3‐year OS: 83.0% versus 82.4%, p = 0.660]. After 1:1 propensity score matching, we found that the patients using Escalated‐R‐CHOP‐21 had statistically significant survival benefits relative to Standard‐R‐CHOP‐21 among the 96 matched elderly male patients for 3‐year PFS [75.5% (95% CI 62.8–88.2) versus 58.2% (95% CI 44.3–72.1); p = 0.019] and 3‐year OS [86.6% (95% CI 76.4–96.8) versus 65.8% (95% CI 52.1–79.5); p = 0.017]. However, no differences in survival were observed for younger male patients. Furthermore, the dose effect in PFS of Escalated‐R‐CHOP‐21 was more obvious for elderly male patients with no high‐risk extranodal sites (p = 0.005 and interaction p = 0.030). Conclusion Escalated‐R‐CHOP‐21 could be a safe and effective option for treating elderly male patients with DLBCL. This study provides new insight into optimizing the standard treatment regimen, which may have important therapeutic implications in elderly male patients with DLBCL.
- Published
- 2021
- Full Text
- View/download PDF
13. Clinical actionability of triaging DNA mismatch repair deficient colorectal cancer from biopsy samples using deep learning
- Author
-
Wu Jiang, Wei-Jian Mei, Shuo-Yu Xu, Yi-Hong Ling, Wei-Rong Li, Jin-Bo Kuang, Hao-Sen Li, Hui Hui, Ji-Bin Li, Mu-Yan Cai, Zhi-Zhong Pan, Hui-Zhong Zhang, Li Li, and Pei-Rong Ding
- Subjects
Colorectal cancer ,Mismatch repair-deficient ,Deep learning ,Screening strategy ,Dual-threshold ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: We aimed to develop a deep learning (DL) model to predict DNA mismatch repair (MMR) status in colorectal cancers (CRC) based on hematoxylin and eosin-stained whole-slide images (WSIs) and assess its clinical applicability. Methods: The DL model was developed and validated through three-fold cross validation using 441 WSIs from the Cancer Genome Atlas (TCGA) and externally validated using 78 WSIs from the Pathology AI Platform (PAIP), and 355 WSIs from surgical specimens and 341 WSIs from biopsy specimens of the Sun Yet-sun University Cancer Center (SYSUCC). Domain adaption and multiple instance learning (MIL) techniques were adopted for model development. The performance of the models was evaluated using the area under the receiver operating characteristic curve (AUROC). A dual-threshold strategy was also built from the surgical cohorts and validated in the biopsy cohort. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), F1-score, and the percentage of patients avoiding IHC testing were evaluated. Findings: The MIL model achieved an AUROC of 0·8888±0·0357 in the TCGA-validation cohort, 0·8806±0·0232 in the PAIP cohort, 0·8457±0·0233 in the SYSUCC-surgical cohort, and 0·7679±0·0342 in the SYSUCC-biopsy cohort. A dual-threshold triage strategy was used to rule-in and rule-out dMMR patients with remaining uncertain patients recommended for further IHC testing, which kept sensitivity higher than 90% and specificity higher than 95% on deficient MMR patient triage from both the surgical and biopsy specimens, result in more than half of patients avoiding IHC based MMR testing. Interpretation: A DL-based method that could directly predict CRC MMR status from WSIs was successfully developed, and a dual-threshold triage strategy was established to minimize the number of patients for further IHC testing. Funding: The study was funded by the National Natural Science Foundation of China (82073159, 81871971 and 81700576), the Natural Science Foundation of Guangdong Province (No. 2021A1515011792 and No.2022A1515012403) and Medical Scientific Research Foundation of Guangdong Province of China (No. A2020392).
- Published
- 2022
- Full Text
- View/download PDF
14. Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?
- Author
-
Jing‐Sheng Cai, Shuo Li, Shu‐Mei Yan, Jie Yang, Mu‐Zi Yang, Chu‐Long Xie, Ji‐Bin Li, Yan‐Fen Feng, Hao‐Xian Yang, and Xue Hou
- Subjects
major pathologic response ,nodal downstaging ,non small‐cell lung cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (NAC) and surgery. Methods A total of 194 eligible cases were included. Tumor pathologic response and node status were assessed. Based on these evaluations, patients were divided into the MPR group and the non‐MPR group, the nodal downstaging (ND) group and non‐ND group. Furthermore, patients were assigned into four subgroups (MPR + ND, MPR + non‐ND, non‐MPR + ND, and non‐MPR + non‐ND). Overall survival (OS) and disease‐free survival (DFS) were compared between groups. Multivariate analyses were performed to identify prognostic factors. Results MPR was identified in 32 patients and ND was present in 108 patients. OS and DFS were better in the MPR group than in the non‐MPR group, but with no statistical significance (OS, p = 0.158; DFS, p = 0.126). The ND group had better OS than the non‐ND group (p = 0.031). However, the DFS between these two groups was comparable (p = 0.103). Further analyses suggested that both OS and DFS were better in the MPR + ND group than in the non‐MPR + non‐ND group (OS, p = 0.017; DFS, p = 0.029). Multivariate analyses confirmed that MPR + ND was an independent favorable predictor. Conclusions MPR combined with ND could improve the predictive value on survival in NSCLC patients receiving NAC.
- Published
- 2021
- Full Text
- View/download PDF
15. Learning curve of robotic portal lobectomy for pulmonary neoplasms: A prospective observational study
- Author
-
Mu‐Zi Yang, Ren‐Chun Lai, Abbas E. Abbas, Bernard J. Park, Ji‐Bin Li, Jie Yang, Jin‐Chun Wu, Gang Wang, and Hao‐Xian Yang
- Subjects
learning curve ,lung neoplasm ,robotic surgery ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We aim to assess the learning curve of robotic portal lobectomy with four arms (RPL‐4) in patients with pulmonary neoplasms using prospectively collected data. Methods Data from 100 consecutive cases with lung neoplasms undergoing RPL‐4 were prospectively accumulated into a database between June 2018 and August 2019. The Da Vinci Si system was used to perform RPL‐4. Regression curves of cumulative sum analysis (CUSUM) and risk‐adjusted CUSUM (RA‐CUSUM) were fit to identify different phases of the learning curve. Clinical indicators and patient characteristics were compared between different phases. Results The mean operative time, console time, and docking time for the entire cohort were 130.6 ± 53.8, 95.5 ± 52.3, and 6.4 ± 3.0 min, respectively. Based on CUSUM analysis of console time, the surgical experience can be divided into three different phases: 1–10 cases (learning phase), 11–51 cases (plateau phase), and >51 cases (mastery phase). RA‐CUSUM analysis revealed that experience based on 56 cases was required to truly master this technique. Total operative time (p
- Published
- 2021
- Full Text
- View/download PDF
16. Gender Differences in Factors Associated with Clinically Meaningful Weight Loss among Adults Who Were Overweight or Obese: A Population-Based Cohort Study
- Author
-
Ji-Bin Li, Zhi-Yu Qiu, Zhen Liu, Qian Zhou, Li-Fen Feng, Jun-Dong Li, and Xi Zhang
- Subjects
predictors ,clinically meaningful weight loss ,gender difference ,adults ,Nutrition. Foods and food supply ,TX341-641 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Objectives: The impact of heterogeneity on gender difference for achieving clinically meaningful weight loss (cmWL) remains unclear. Here, we explored the potential gender differences in factors associated with cmWL. Methods: A total of 60,668 participants with body mass index (BMI) ≥25 kg/m2 at study entry and available BMI values at follow-up were included in this study. cmWL was defined as a weight loss of ≥5% from the study entry to follow-up. The associations of social-demographic factors, personal history of chronic diseases, lifestyle behaviors, and history of BMI with cmWL were evaluated using logistic regression models. Results: During a median follow-up of 9.13 years, 26.6% of the participants had a cmWL (30.8% for females vs. 23.1% in males; p < 0.001). Participants with older age, obesity at study entry, being more physical activity compared to 10 years ago, being relapsed smokers or consistent current smokers, having a history of chronic diseases (i.e., diabetes, osteoporosis, and stroke), cancer diagnosis during the study period, and more than 10-year follow-up were more likely to achieve cmWL in both males and females (all p < 0.05). The new smoking quitters and participants with less active in physical activity compared to 10 years ago were less likely to achieve cmWL in both males and females (all p < 0.05). Specifically, males with a history of emphysema were more likely to reach cmWL, and for females, those being overweight at 20 years old and current drinkers were more likely to reach cmWL (p < 0.05). Sensitivity analyses demonstrated similar results. Conclusion: Age, BMI status, physical activity, smoking status, family income, and health status were independent factors in males and females for weight management. However, further well-designed prospective studies are warranted to confirm our findings.
- Published
- 2020
- Full Text
- View/download PDF
17. Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
- Author
-
Nai-Bin Chen, Qi-Wen Li, Zheng-Fei Zhu, Yi-Ming Wang, Zhangkai J. Cheng, Zhou-Guang Hui, Su-Ping Guo, Hao-Qiang He, Bin Wang, Xiao-Yan Huang, Ji-Bin Li, Jin-Yu Guo, Nan Hu, Xin-Lei Ai, Yin Zhou, Da-Quan Wang, Fang-Jie Liu, Chuan-Miao Xie, Bo Qiu, and Hui Liu
- Subjects
Gross tumor volume ,The integrated GTV-TNM stratification system ,Locally advanced non-small cell lung cancer ,Concurrent chemoradiotherapy ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose The gross tumor volume (GTV) could be an independent prognostic factor for unresectable locally advanced non-small cell lung cancer (LANSCLC). We aimed to develop and validate a novel integrated GTV-TNM stratification system to supplement LANSCLC sub-staging in patients treated with concurrent chemoradiotherapy (CCRT). Methods We performed a retrospective review of 340 patients with unresectable LANSCLC receiving definitive CCRT. All included patients were divided into two randomized cohorts. Then the Kaplan–Meier method and Cox regression were calculated to access the prognostic value of the integrated GTV-TNM stratification system, which was further validated by the area under the receiver operating characteristic curve (AUC) score and F1-score. Results The optimal outcome-based GTV cut-off values (70 and 180 cm3) of the modeling cohort were used to determine each patient’s integrated GTV-TNM stratum in the whole cohort. Our results indicated that a lower integrated GTV-TNM stratum could had better overall survival and progression-free survival (all P
- Published
- 2020
- Full Text
- View/download PDF
18. Longitudinal associations between BMI change and the risks of colorectal cancer incidence, cancer-relate and all-cause mortality among 81,388 older adults
- Author
-
Ji-Bin Li, Sheng Luo, Martin C. S. Wong, Cai Li, Li-Fen Feng, Jian-Hong Peng, Jing-Hua Li, and Xi Zhang
- Subjects
BMI change ,Colorectal cancer risk ,Mortality ,Older adults ,Longitudinal association ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background It remains controversial whether weight change could influence the risks of colorectal cancer (CRC) and mortality. This study aimed to quantify the associations between full-spectrum changes in body mass index (BMI) and the risks of colorectal cancer (CRC) incidence, cancer-related and all-cause mortality among midlife to elder population. Methods A total of 81,388 participants who were free of cancer and aged 55 to 74 years from the Prostate, Lung, Colorectal, and Ovarian (PLCO) screening program were involved. The percentage change of BMI was calculated as (BMI in 2006 - BMI at baseline)/BMI at baseline, and was categorized into nine groups: decrease (≥ 15.0%, 10.0–14.9%, 5.0–9.9%, 2.5–4.9%), stable (decrease/increase
- Published
- 2019
- Full Text
- View/download PDF
19. Roles of Psychosocial Factors on the Association Between Online Social Networking Use Intensity and Depressive Symptoms Among Adolescents: Prospective Cohort Study
- Author
-
Ji-Bin Li, Li-Fen Feng, Anise M S Wu, Jin-Chen Mai, Yu-Xia Chen, Phoenix K H Mo, and Joseph T F Lau
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe potential mechanisms underlying the association between online social networking use intensity and depressive symptoms are unclear and underresearched. ObjectiveWe aimed to investigate the potential roles of interpersonal psychosocial factors on the association between online social networking use intensity and depressive symptoms among early adolescents. MethodsA total of 4237 adolescents from a 9-month longitudinal study were included. Score changes (indicated as △) for the social function use intensity (SFUI) and entertainment function use intensity (EFUI) subscales of the Online Social Networking Activity Intensity Scale and for friendship quality, perceived family support, perceived friend support, parent–adolescent conflict, social nonconfidence, and depressive symptoms were analyzed. The potential mediation effects of unfavorable psychosocial factors and suppression effects of favorable psychosocial factors on the association of △SFUI with △CES-D and the association of △EFUI with △CES-D were tested using hierarchical regression models. ResultsThe association between △SFUI and △CES-D was partially mediated by △mother–adolescent conflict (mediation effect size 5.11%, P=.02) and △social nonconfidence (mediation effect size 20.97%, P
- Published
- 2021
- Full Text
- View/download PDF
20. Radiation Oncologists’ Perceptions of Adopting an Artificial Intelligence–Assisted Contouring Technology: Model Development and Questionnaire Study
- Author
-
Huiwen Zhai, Xin Yang, Jiaolong Xue, Christopher Lavender, Tiantian Ye, Ji-Bin Li, Lanyang Xu, Li Lin, Weiwei Cao, and Ying Sun
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Public aspects of medicine ,RA1-1270 - Abstract
BackgroundAn artificial intelligence (AI)–assisted contouring system benefits radiation oncologists by saving time and improving treatment accuracy. Yet, there is much hope and fear surrounding such technologies, and this fear can manifest as resistance from health care professionals, which can lead to the failure of AI projects. ObjectiveThe objective of this study was to develop and test a model for investigating the factors that drive radiation oncologists’ acceptance of AI contouring technology in a Chinese context. MethodsA model of AI-assisted contouring technology acceptance was developed based on the Unified Theory of Acceptance and Use of Technology (UTAUT) model by adding the variables of perceived risk and resistance that were proposed in this study. The model included 8 constructs with 29 questionnaire items. A total of 307 respondents completed the questionnaires. Structural equation modeling was conducted to evaluate the model’s path effects, significance, and fitness. ResultsThe overall fitness indices for the model were evaluated and showed that the model was a good fit to the data. Behavioral intention was significantly affected by performance expectancy (β=.155; P=.01), social influence (β=.365; P
- Published
- 2021
- Full Text
- View/download PDF
21. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
- Author
-
Feng Wang, Ming-Ming He, Yi-Chen Yao, Xia Zhao, Zhi-Qiang Wang, Ying Jin, Hui-Yan Luo, Ji-Bin Li, Feng-Hua Wang, Miao-Zhen Qiu, Zhi-Da Lv, De-Shen Wang, Yu-Hong Li, Dong-Sheng Zhang, and Rui-Hua Xu
- Subjects
colorectal cancer ,immunotherapy ,regorafenib ,toripalimab ,programmed cell death protein 1 ,microbiome ,Medicine (General) ,R5-920 - Abstract
Summary: This is a phase Ib/II study of regorafenib plus toripalimab for colorectal cancer. The objective response rate (ORR) is 15.2% and the disease control rate is 36.4% in evaluable patients with recommended phase II dose (80 mg regorafenib plus toripalimab). The median progression-free survival (PFS) and the median overall survival are 2.1 months and 15.5 months, respectively. Patients with liver metastases have lower ORR than those without (8.7% versus 30.0%). All patients (3/3) with lung-only metastasis respond, whereas no patients (0/4) with liver-only metastasis respond. 94.9% and 38.5% of patients have grade 1 and grade 3 treatment-related adverse events, respectively. Gut microbiome analysis of the baseline fecal samples shows significantly increased relative abundance and positive detection rate of Fusobacterium in non-responders than responders. Patients with high-abundance Fusobacterium have shorter PFS than those with low abundance (median PFS = 2.0 versus 5.2 months; p = 0.002).
- Published
- 2021
- Full Text
- View/download PDF
22. Tobacco smoking and trends in histological subtypes of female lung cancer at the Cancer Hospital of the Chinese Academy of Medical Sciences over 13 years
- Author
-
Qiang Zeng, Emily Vogtmann, Man‐man Jia, Mark Parascandola, Ji‐bin Li, Yan‐ling Wu, Qin‐fu Feng, and Xiao‐nong Zou
- Subjects
female ,histology ,Lung neoplasms ,smoking ,trends ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Lung cancer is the leading cause of cancer mortality among women in China, and incidence and mortality continue to rise despite the fact that smoking prevalence is very low among Chinese women. Aim This study investigated tobacco smoking and trends in histological subtypes of female lung cancer in a central cancer hospital in China. Methods Demographic, smoking history and histological information on female lung cancer patients diagnosed or treated from 2000 to 2012 was collected from the Cancer Hospital, Chinese Academy of Medical Science (CHCAMS). The classification of histological subtypes and clinical stages were conducted using the ICD‐O‐3 and Eighth AJCC Cancer Staging Manuals. Time‐trends of histological subtypes were analyzed based on annual percentage change (APC). Results Overall, 5870 female cases of lung cancer were included in the analysis. The number of female lung cancer patients increased from 509 (2000–2002) to 1744 (2011–2012). The most common histological type of lung cancer was adenocarcinoma (ADC) (72.93%), followed by small cell lung cancer (SCLC) (11.06%), squamous cell carcinoma (SCC) (8.38%) and other (7.63%). Among smokers, the proportion of SCC decreased from 40.5% to 23.7% (P = 0.005), while ADC increased from 35.7% to 50.7% (P = 0.009). In non‐smokers, ADC increased from 63.1% to 80.6% (P = 0.006) and SCC decreased from 13.6% to 4.5% (P = 0.016). Among SCC cases, smokers made up a larger proportion of early stage (I/II: 47.1%) compared with late stages (III, 34.3%; IV, 18.6%). Conclusion The number of female lung cancer patients has increased in CHCAMS. In both smoking and non‐smoking cases, the proportion of adenocarcinoma increased. Squamous cell carcinomas were more likely to be diagnosed in early stages among smokers.
- Published
- 2019
- Full Text
- View/download PDF
23. Systematic review of single-incision versus conventional multiport laparoscopic surgery for sigmoid colon and rectal cancer
- Author
-
Xin Liu, Ji-bin Li, Gang Shi, Rui Guo, and Rui Zhang
- Subjects
Single-incision ,Meta-analysis ,Laparoscopic surgery ,Sigmoid colon and rectal cancer ,Surgery ,RD1-811 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Objectives To explore whether single-incision laparoscopic surgery (SILS) has the better short-term clinical and pathological outcomes than conventional multiport laparoscopic surgery (CLS) for sigmoid colon and rectal cancer. Methods A literature investigation of MEDLINE, PubMed, Ovid, Embase, Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure (CNKI), Chinese Biological Medicine (CBM), and Wanfang databases for relevant researches was performed. Fixed effects and random effects models were used to calculate the corresponding outcomes. Standardized mean difference and risk ratio were calculated for continuous and dichotomous variables separately. Results Nine clinical controlled trials were composed of two randomized clinical trials and seven non-randomized clinical trials with a total of 829 patients. Two hundred ninety-nine (36.1%) patients underwent SILS, and 530 (63.9%) patients underwent CLS. The meta-analysis showed that SILS had more lymph node resection (SMD − 0.25, 95% CI − 0.50 to − 0.002) and less defecation time (SMD − 0.46, 95% CI − 0.75 to − 0.17), exhaust time (SMD − 0.46, 95% CI − 0.75 to − 0.18), and hospital stay (SMD − 0.30, 95% CI − 0.45 to − 0.15 than CLS. SILS was also accompanied with shorter incision length (SMD − 2.46, 95% CI − 4.02 to − 0.90), less pain score (SMD − 0.56, 95% CI − 0.91 to − 0.21), and lower complication rate (RR 0.66, 95% CI 0.47 to 0.91). Blood loss, operative time, distal margin, conversion rate, anastomotic fistula, readmission, local recurrence, and distant metastasis showed no statistical differences in two groups. In all subgroup analysis, SILS also had advantages of incision length, operative time, defecation time, exhaust time, and hospitalization time than CLS. Conclusion SILS could be a more safe and reliable surgical technique than CLS for sigmoid colon and rectal cancer. However, further high-quality studies between these two techniques need to be further developed.
- Published
- 2018
- Full Text
- View/download PDF
24. Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma
- Author
-
Ji-Bin Li, Shan-Shan Guo, Lin-Quan Tang, Ling Guo, Hao-Yuan Mo, Qiu-Yan Chen, and Hai-Qiang Mai
- Subjects
longitudinal trend ,health-related quality of life ,cheomotherapy ,nasopharyngeal carcinoma ,radiotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and Aims: To investigate the longitudinal trend of health-related quality of life (HRQOL) from the start to the end of concurrent chemoradiotherapy and survival in patients with advanced nasopharyngeal carcinoma (NPC).Methods: A total of 145 patients with stage II–IVb NPC, who were a subsample of a randomized phase III clinical trial, were recruited in this study. HRQOL was measured weekly for a total of 6 weeks during concurrent chemoradiotherapy by the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30. Longitudinal trends of HRQOL domains over time were analyzed using mixed models. Survival rates were estimated using Kaplan-Meier method.Results: During a median follow-up of 45 months, the 3-year progression-free survival rate, overall survival rate, and distant metastasis-free survival rate were highly at 86.8% (95% CI: 80.1%, 91.4%), 95.1% (95% CI: 90.1%, 97.6%), and 91.0% (95% CI: 84.9%, 94.6%), respectively. The average weekly declines of five functioning domains were 1.83–3.52 points during the treatment period, with role functioning having the largest decline rate (−2.52 points per week, 95% CI: −4.50, −2.55; p < 0.001). Loss of appetite is the most affected symptom, with severe appetite loss ranging from 35.9 to 61.1%. The average increases of symptoms were 0.63–5.16 points per week during treatment period (all p-values for time
- Published
- 2020
- Full Text
- View/download PDF
25. Prevalence and temporal trends of presarcopenia metrics and related body composition measurements from the 1999 to 2006 NHANES
- Author
-
Xi Zhang, Ji-Bin Li, Yuwan Wu, Dantong Gu, and Huajun Li
- Subjects
Medicine - Abstract
Objective To evaluate the prevalence and temporal trends of presarcopenia and related body composition measurements.Design Cross-sectional study.Setting National Health and Nutrition Examination Survey (NHANES) 1999–2006.Methods Presarcopenia was defined according to the guidelines from the European Working Group on Sarcopenia. Logistic or linear regression models were used to evaluate the linear trend of the prevalence of presarcopenia, obesity and related body composition measurements.Participants A total of 29 947 participants aged 18–90 years from five waves of the NHANES were included in the analysis.Outcome measures Presarcopenia was sex-specifically defined as having a skeletal mass index ≤7.26 kg/m2 in men and ≤5.5 kg/m2 in women. Body composition measurements, including total body fat percentage, total body fat mass, total lean body mass, appendicular skeletal muscle mass and bone mineral density, were obtained by dual-energy X-ray absorptiometry.Results The overall prevalence of presarcopenia ranged from 16.4% in 1999–2000 to 14.8% in 2005–2006 (p for trend=0.78). Presarcopenia was stable in both males (p for trend=0.36) and females (p for trend=0.20). The presarcopenia prevalence was significantly elevated among the age group of 18–39 years old (from 11.3% to 14.1%, p for trend=0.04) and among non-Hispanic blacks (p for trend
- Published
- 2020
- Full Text
- View/download PDF
26. Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status
- Author
-
Jing Zhao, Ji-bin Li, Jing-yan Wang, Yu-liang Wang, Da-wei Liu, Xin-bei Li, Yu-kun Song, Yi-su Tian, Xu Yan, Zhu-hao Li, Shao-fu He, Xiao-long Huang, Li Jiang, Zhi-yun Yang, and Jian-ping Chu
- Subjects
Computer applications to medicine. Medical informatics ,R858-859.7 ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Background and purpose: Neurite orientation dispersion and density imaging (NODDI) is a new diffusion MRI technique that has rarely been applied for glioma grading. The purpose of this study was to quantitatively evaluate the diagnostic efficiency of NODDI in tumour parenchyma (TP) and peritumoural area (PT) for grading gliomas and detecting isocitrate dehydrogenase-1 (IDH-1) mutation status. Methods: Forty-two patients (male: 23, female: 19, mean age: 44.5 y) were recruited and underwent whole brain NODDI examination. Intracellular volume fraction (icvf) and orientation dispersion index (ODI) maps were derived. Three ROIs were manually placed on TP and PT regions for each case. The corresponding average values of icvf and ODI were calculated, and their diagnostic efficiency was assessed. Results: Tumours with high icvfTP (≥0.306) and low icvfPT (≤0.331) were more likely to be high-grade gliomas (HGGs), while lesions with low icvfTP (0.331) were prone to be low-grade gliomas (LGGs) (P
- Published
- 2018
- Full Text
- View/download PDF
27. Novel lactobacillus consortium for effective zearalenone adsorption and biodegradation
- Author
-
Murtaza, Bilal, Wang, Lili, Li, Xiaoyu, Ali, Ashiq, Haq, Shahbaz Ul, Ji-bin, Li, and Xu, Yongping
- Published
- 2024
- Full Text
- View/download PDF
28. The independent impacts of perceived immediate and future benefits of internet gaming on internet gaming disorder among adolescent internet gamers in China: Mediation via internet gaming time.
- Author
-
Yanqiu Yu, Vivian W. I. Fong, Ji-bin Li, Jianxin Zhang, and Joseph Tak Fai Lau
- Published
- 2023
- Full Text
- View/download PDF
29. Genome analysis of Salmonella phage vB_SalM_8-19 (genus Rosemountvirus)
- Author
-
Cong, Cong, Bing Dong, Wei, Hui Jing, Cui, Yu Yu, Yuan, Yong Ping, Xu, Li Li, Wang, Shu Ying, Li, Ji Bin, Li, Mu, Xu, and Xiao Yu, Li
- Published
- 2021
- Full Text
- View/download PDF
30. Overall Survival Rates Become Similar Between Percutaneous Ablation and Hepatic Resection With Increasing Age Among Elderly Patients With Early Hepatocellular Carcinoma
- Author
-
Hong Liang Zou, Hui Tang, Chao An, Lu Jun Shen, Ji Bin Li, Wan Yee Lau, Yi Quan Jiang, and Jin Hua Huang
- Subjects
Cancer Research ,Oncology - Published
- 2023
31. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study
- Author
-
Shao-Hua Li, Jie Mei, Yuan Cheng, Qiang Li, Qiao-Xuan Wang, Chong-Kai Fang, Qiu-Cheng Lei, Hua-Kun Huang, Ming-Rong Cao, Rui Luo, Jing-Duo Deng, Yu-Chuan Jiang, Rong-Ce Zhao, Liang-He Lu, Jing-Wen Zou, Min Deng, Wen-Ping Lin, Ren-Guo Guan, Yu-Hua Wen, Ji-Bin Li, Lie Zheng, Zhi-Xing Guo, Yi-Hong Ling, Huan-Wei Chen, Chong Zhong, Wei Wei, and Rong-Ping Guo
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI). PATIENTS AND METHODS In this randomized, open-label, multicenter trial, histologically confirmed HCC patients with MVI were randomly assigned (1:1) to receive adjuvant FOLFOX-HAIC (treatment group) or routine follow-up (control group). The primary end point was disease-free survival (DFS) by intention-to-treat (ITT) analysis while secondary end points were overall survival, recurrence rate, and safety. RESULTS Between June 2016 and August 2021, a total of 315 patients (ITT population) at five centers were randomly assigned to the treatment group (n = 157) or the control group (n = 158). In the ITT population, the median DFS was 20.3 months (95% CI, 10.4 to 30.3) in the treatment group versus 10.0 months (95% CI, 6.8 to 13.2) in the control group (hazard ratio, 0.59; 95% CI, 0.43 to 0.81; P = .001). The overall survival rates at 1 year, 2 years, and 3 years were 93.8% (95% CI, 89.8 to 98.1), 86.4% (95% CI, 80.0 to 93.2), and 80.4% (95% CI, 71.9 to 89.9) for the treatment group and 92.0% (95% CI, 87.6 to 96.7), 86.0% (95% CI, 79.9 to 92.6), and 74.9% (95% CI, 65.5 to 85.7) for the control group (hazard ratio, 0.64; 95% CI, 0.36 to 1.14; P = .130), respectively. The recurrence rates were 40.1% (63/157) in the treatment group and 55.7% (88/158) in the control group. Majority of the adverse events were grade 0-1 (83.8%), with no treatment-related death in both groups. CONCLUSION Postoperative adjuvant HAIC with FOLFOX significantly improved the DFS benefits with acceptable toxicities in HCC patients with MVI.
- Published
- 2023
32. Comparison of Short-Term Outcomes Between Robot-Assisted and Video-Assisted Segmentectomy for Small Pulmonary Nodules: A Propensity Score-Matching Study
- Author
-
Mu-Zi Yang, Zi-Hui Tan, Ji-Bin Li, Chu-Long Xie, Tian-Yu Sun, Hao Long, Jian-Hua Fu, Lan-Jun Zhang, Peng Lin, and Hao-Xian Yang
- Subjects
Oncology ,Surgery - Published
- 2023
33. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
- Author
-
Zhi-Qiang, Wang, Qi, Mei, Ji-Bin, Li, Rui, You, You-Ping, Liu, Rui, Sun, Guang-Yuan, Hu, Ming-Yuan, Chen, and Yi-Jun, Hua
- Published
- 2019
- Full Text
- View/download PDF
34. Associations of intensity and emotional connection related to online social networking use on the risk of incident depression among Chinese adolescents: A prospective cohort study
- Author
-
Ji-Bin Li, Joseph T.F. Lau, Li-Fen Feng, Xi Zhang, Jing-Hua Li, Jin-Chen Mai, Yu-Xia Chen, and Phoenix K.H. Mo
- Subjects
China ,Psychiatry and Mental health ,Clinical Psychology ,Adolescent ,Depression ,Online Social Networking ,Humans ,Prospective Studies ,Social Networking - Abstract
To investigate the longitudinal prediction of intensity and emotional connection (EC) related to online social networking use at baseline on the risk of incident depression at nine-month follow-up among adolescents.A total of 3196 secondary school students, who were online social networking users and free of depression at baseline, were included in this study. Multilevel logistic regression models were applied to investigate the longitudinal prediction of two dimensions of online social networking use intensity (social function use intensity (SFUI), entertainment function use intensity (EFUI)) and EC scores at baseline on incident depression at follow-up.The incidence of depression was 23.37 per 100-person-years during a nine-month follow-up period. Baseline SFUI and EFUI scores were significantly associated with higher level of incident depression (adjusted OR = 1.017, 95% CI: 1.004-1.029 for SFUI, p = 0.010; adjusted OR = 1.046, 95% CI: 1.012-1.080 for EFUI, p = 0.007), after adjustment of significant background factors and baseline depressive symptom score. The associations of EC at baseline and its interaction with SFUI and EFUI on incident depression were statistically non-significant.Online social networking use seems be a risk factor of depression among adolescents, regardless of its specific functions. Early intervention is recommended to reduce the level of online social networking use intensity as a means of preventing depression among adolescents.
- Published
- 2022
35. <scp>Short‐term</scp> outcomes of robotic lobectomy versus video‐assisted lobectomy in patients with pulmonary neoplasms
- Author
-
Tian‐Yu Sun, Chu‐Long Xie, Zihui Tan, Ji‐Bin Li, Mu‐Zi Yang, and Hao‐Xian Yang
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Published
- 2023
36. Impact of the Number of Harvested Lymph Nodes on Long-term Survival in Node-Negative Non-small Cell Lung Cancer: Based on Clinical Stage but Not Pathological Stage
- Author
-
Mu-Zi Yang, Zi-Hui Tan, Ji-Bin Li, Hao Long, Jian-Hua Fu, Lan-Jun Zhang, Peng Lin, Hou Xue, and Hao-Xian Yang
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Oncology - Published
- 2023
37. Station <scp>3A</scp> lymph node dissection does not improve <scp>long‐term</scp> survival in <scp>right‐side</scp> operable <scp>non‐small</scp> ‐cell lung cancer patients: A propensity score matching study
- Author
-
Mu‐Zi Yang, Zi‐Hui Tan, Ji‐Bin Li, Hao Long, Jian‐Hua Fu, Lan‐Jun Zhang, Peng Lin, Xue Hou, and Hao‐Xian Yang
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,General Medicine - Published
- 2022
38. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial
- Author
-
Xiao-Yun Li, Dong-Hua Luo, Ling Guo, Hao-Yuan Mo, Rui Sun, Shan-Shan Guo, Li-Ting Liu, Zhen-Chong Yang, Jin-Hao Yang, Fang Qiu, Xue-Song Sun, Pan Wang, Qing Liu, Ji-Bin Li, Qing-Nan Tang, Chao Lin, Qi Yang, Sai-Lan Liu, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Chun-Yan Guo, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Lin-Quan Tang, and Hai-Qiang Mai
- Subjects
Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Cancer Research ,Nasopharyngeal Carcinoma ,Nasopharyngeal Neoplasms ,Chemoradiotherapy ,DNA ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Quality of Life ,Humans ,Cisplatin ,Neoplasm Recurrence, Local ,Retrospective Studies - Abstract
PURPOSE Cumulative doses of 200 mg/m2 for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiority of a two-cycle 100 mg/m2 concurrent DDP regimen over three-cycle in patients with low-risk LA-NPC with pretreatment Epstein-Barr virus DNA levels < 4,000 copies/mL. PATIENTS AND METHODS Eligible patients were randomly assigned 1:1 to receive two cycles or three cycles concurrent DDP-based chemoradiotherapy. The primary end point was 3-year progression-free survival (PFS). The secondary end points included overall survival, distant metastasis-free survival, locoregional relapse-free survival, etc. RESULTS Between September 2016 and October 2018, 332 patients were enrolled, with 166 in each arm. After a median follow-up of 37.7 months, the estimated 3-year PFS rates were 88.0% in the two-cycle group and 90.4% in the three-cycle group, with a difference of 2.4% (95% CI, –4.3 to 9.1, Pnoninferiority = .014). No differences were observed between groups in terms of PFS, overall survival, and the cumulative incidences of locoregional relapse and distant metastasis. Patients in the three-cycle group developed significantly more grade 3-4 mucositis (41 [24.8%] v 25 [15.1%]), hyponatremia (26 [15.8%] v 14 [8.4%]), and dermatitis (9 [5.5%] v 2 [1.2%]). The overall all-grade and grade 3-4 toxicity burdens were heavier in three-cycle group (T-scores, 12.33 v 10.57, P < .001 for all grades; 1.76 v 1.44, P = .05 for grade 3-4). Patients in the three-cycle group also showed more all-grade hearing impairment, dry mouth and skin fibrosis, and impaired long-term quality of life. CONCLUSION Intensity-modulated radiotherapy plus two cycles of concurrent 100 mg/m2 DDP could be an alternative treatment option for patients with low-risk LA-NPC.
- Published
- 2022
39. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial
- Author
-
Ling-Long Tang, Cheng-Long Huang, Ning Zhang, Wei Jiang, Yi-Shan Wu, Shao Hui Huang, Yan-Ping Mao, Qing Liu, Ji-Bin Li, Shao-Qiang Liang, Guan-Jie Qin, Wei-Han Hu, Ying Sun, Fang-Yun Xie, Lei Chen, Guan-Qun Zhou, and Jun Ma
- Subjects
Adult ,Nasopharyngeal Carcinoma ,Adolescent ,Nasopharyngeal Neoplasms ,Chemoradiotherapy ,Middle Aged ,Young Adult ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Cisplatin ,Neoplasm Recurrence, Local ,Aged ,Neoplasm Staging - Abstract
The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma.This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed.Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pElective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma.Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation.For the Chinese translation of the abstract see Supplementary Materials section.
- Published
- 2022
40. Defining the Learning Curve of Robotic Portal Segmentectomy in Small Pulmonary Lesions: A Prospective Observational Study
- Author
-
Mu-Zi Yang, Zi-Hui Tan, Abbas E. Abbas, Ji-Bin Li, Chu-Long Xie, Hao Long, Lan-Jun Zhang, Jian-Hua Fu, Peng Lin, and Hao-Xian Yang
- Subjects
Health Informatics ,Surgery - Abstract
Although robotic segmentectomy has been applied for the treatment of small pulmonary lesions for many years, studies on the learning curve of robotic segmentectomy are quite limited. Thus, we aim to investigate the learning curve of robotic portal segmentectomy with 4 arms (RPS-4) using prospectively collected data in patients with small pulmonary lesions. One hundred consecutive patients with small pulmonary lesions who underwent RPS-4 between June 2018 and April 2021 were included in the study. Da Vinci Si/Xi systems were used to perform RPS-4. The mean operative time, console time, and docking time for the entire cohort were 119.2 ± 41.6, 85.0 ± 39.6, and 6.6 ± 2.8 minutes, respectively. The learning curve of RPS-4 can be divided into three different phases: 1–37 cases (learning phase), 38–78 cases (plateau phase), and > 78 cases (mastery phase). Moreover, 64 cases were required to ensure acceptable surgical outcomes. The total operative time (P
- Published
- 2022
41. ASO Visual Abstract: Comparison of Short-Term Outcomes Between Robot-Assisted and Video-Assisted Segmentectomy for Small Pulmonary Nodules—A Propensity Score Matching Study
- Author
-
Mu-Zi Yang, Zi-Hui Tan, Ji-Bin Li, Chu-Long Xie, Tian-Yu Sun, Hao Long, Jian-Hua Fu, Lan-Jun Zhang, Peng Lin, and Hao-Xian Yang
- Subjects
Oncology ,Surgery - Published
- 2023
42. The effect of standard dose of neo/adjuvant chemotherapy on the benefit from capecitabine maintenance therapy: an exploratory analysis from SYSUCC-001 trial
- Author
-
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Zhong-Yu Yuan, and Qian-Jun Chen
- Abstract
Aims: The addition of extended capecitabine after standard neo/adjuvant chemotherapy shows controversial results in triple-negative breast cancer (TNBC) patients between SYSUCC-001 trial and CIBOMA trial. Patients presents different responses to diverse regimens, and different dose strengths also affect their prognosis. Hence, we tried to investigate whether the benefit from SYSUCC-001 is effected by the strength of previous adjuvant chemotherapy. Methods: We reviewed the neo/adjuvant chemotherapy regimens, dose divide by body surface area, etc. of TNBC patients in SYSUCC-001 trial. Their therapeutic dose were classified into consistent and inconsistent with CIBOMA trial. Besides, we stratified patients into the strong regimen arm (A/EC-T and TA/EC) and medium regimen arm (A/EC, TA/E, CMF, FA/EC, FA/EC-T, and TC) according to their specific neo/adjuvant treatment.Subsequently, we compared differences in baseline characteristics between the strong and medium regimen arms, and further investigated the impact of therapeutic regimens and dose on the survival outcome of TNBC patients in SYSUCC-001 trial(the median follow-up is 61months, interquartile range, 44-82months). Results: A total of 434 TNBC patients were included in this study. Among them, patients who used strong chemotherapy regimen accounted for about 76.74%, and those who used medium regimen accounted for 23.26%. About 32.3% and 52.2% patients received the standard doses of anthracyclines and taxanes separately according to minimum acceptable regimens for chemotherapy in CIBOMA trial. In our analysis we found the dose strength did not affect the DFS in the observe group. However, the standard dose of taxanes improved the DFS in capecitabine group [HR, 2.04 (1.02 - 4.06)]. The interaction analysis showed that the strength of treatment regimenand anthracycline dose did not affect DFS. Whereas, subgroup analysis showed TNBC patients with standard dose of taxanes significantly benefited from capecitabine (P = 0.014). In addition, the standard dose of taxanes could improve DFS. Conclusions: The strength of neo/adjuvant chemotherapy does not affect the curative effect of capecitabine maintenance chemotherapy. The benefits of the SYSUCC-001 study are mainly from one-year capecitabine administration. Moreover, the standard dose of chemotherapy especially taxanes is a positive factor for the effect of capecitabine treatment. So in some special condition, such as patients can’t endure the side effect of the chemotherapy, we’d better reduce the dose of anthracycline not the taxanes.
- Published
- 2022
43. Development and validation of the resource loss due to reduction in gaming time scale among adolescent internet gamers in China
- Author
-
Yanqiu Yu, Ji-bin Li, and Joseph T.F. Lau
- Subjects
Psychiatry and Mental health ,Clinical Psychology ,Medicine (miscellaneous) ,Toxicology - Published
- 2023
44. Bifurcations of limit cycles in a Z6-equivariant planar vector field of degree 7.
- Author
-
Jianping Shi and Ji-Bin Li 0001
- Published
- 2014
- Full Text
- View/download PDF
45. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial
- Author
-
Yan-Ping Mao, Shun-Xin Wang, Tian-Sheng Gao, Ning Zhang, Xiao-Yu Liang, Fang-Yun Xie, Yuan Zhang, Guan-Qun Zhou, Rui Guo, Wei-Jie Luo, Yong-Jie Li, Shao-Qiang Liang, Li Lin, Wen-Fei Li, Xu Liu, Cheng Xu, Yu-Pei Chen, Jia-Wei Lv, Shao-Hui Huang, Li-Zhi Liu, Ji-Bin Li, Ling-Long Tang, Lei Chen, Ying Sun, and Jun Ma
- Subjects
General Medicine - Abstract
Objectives To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma. Design Open-label, non-inferiority, multicentre, randomised, phase 3 trial. Setting Three Chinese hospitals between 20 November 2017 and 3 December 2018. Participants Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement. Interventions Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer Center. Eligible patients were randomly assigned (1:1; block size of four) to receive MRLN sparing radiotherapy or standard radiotherapy (both medial and lateral retropharyngeal lymph node groups), and stratified by institution and treatment modality as follows: radiotherapy alone; concurrent chemoradiotherapy; induction chemotherapy plus radiotherapy or concurrent chemoradiotherapy. Main outcome measures Non-inferiority was met if the lower limit of the one sided 97.5% confidence interval of the absolute difference in three year local relapse-free survival (MRLN sparing radiotherapy minus standard radiotherapy) was greater than −8%. Results 568 patients were recruited: 285 in the MRLN sparing radiotherapy group; 283 in the standard radiotherapy group. Median follow-up was 42 months (interquartile range 39-45), intention-to-treat analysis showed that the three year local relapse-free survival of the MRLN sparing radiotherapy group was non-inferior to that of the standard radiotherapy group (95.3% v 95.5%, stratified hazard ratio 1.04 (95% confidence interval 0.51 to 2.12), P=0.95) with a difference of −0.2% ((one sided 97.5% confidence interval –3.6 to ∞), P non-inferiority v 35.1%, P=0.01) and late dysphagia (24.0% v 34.3%, P=0.008). Patient reported outcomes at three years after MRLN sparing radiotherapy were better in multiple domains after adjusting for the baseline values: global health status (mean difference −5.6 (95% confidence interval –9.1 to –2.0), P=0.002), role functioning (−5.5 (–7.4 to –3.6), P10 points difference). Conclusion Compared with standard radiotherapy, MRLN sparing radiotherapy showed non-inferiority in terms of risk of local relapse with fewer radiation related toxicity and improved patient reported outcomes in patients with non-metastatic nasopharyngeal carcinoma. Trial registration ClinicalTrials.gov NCT03346109
- Published
- 2023
46. Delayed Controller Design in Communication Networks via Positive Output Feedback.
- Author
-
Jing Lei 0008, Zhu-Yuan Yang, and Ji-Bin Li 0001
- Published
- 2013
- Full Text
- View/download PDF
47. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial
- Author
-
Xu Liu, Ling Guo, Fang-Yun Xie, Wei-Han Hu, Ming-Yuan Chen, Qing-Mei He, Zhi-Min Xu, Chu-Qing Zhang, Ying-Lin Peng, Ling-Long Tang, Yan-Ping Mao, Rui Sun, Ji-Bin Li, Athanassios Argiris, Edwin P. Hui, Ying Sun, and Jun Ma
- Subjects
Vascular Endothelial Growth Factor A ,Cancer Research ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,Radiation ,Nasopharyngeal Carcinoma ,Pyridines ,Angiogenesis Inhibitors ,Nasopharyngeal Neoplasms ,Prognosis ,Necrosis ,Oncology ,DNA, Viral ,Disease Progression ,Humans ,Radiology, Nuclear Medicine and imaging ,Neoplasm Recurrence, Local ,Biomarkers - Abstract
We previously demonstrated that real-time monitoring of plasma Epstein-Barr virus DNA (EBV DNA) during chemoradiation therapy defined 4 distinct phenotypic clusters of nasopharyngeal carcinoma. In particular, the treatment-resistant group, defined as detectable EBV DNA at the end of radiation therapy, had the worst prognosis and is thought to have minimal residual disease.This is the first phase 2 trial to use a targeted agent, apatinib (an inhibitor of vascular endothelial growth factor receptor 2 tyrosine kinase), in the treatment-resistant group. Eligible patients had plasma EBV DNA0 copies/mL at the end of radiation therapy (±1 week). Patients received apatinib (500 mg, once daily) until disease progression, unacceptable toxicity, or for a maximum of 2 years. The primary endpoint was disease-free survival (DFS).Twenty-five patients were enrolled and 23 patients who received apatinib were included in the analyses. Three-year DFS was 47.8% and overall survival was 73.9%. Patients with plasma vascular endothelial growth factor-A ≤150 pg/mL at 28 days after the initiation of treatment had significantly better 3-year DFS (66.7% vs 14.3%; P = .041) and overall survival (88.9% vs 42.9%; P = .033). The most common adverse event of grade ≥3 was nasopharyngeal necrosis (26%), oral/pharyngeal pain (22%), and hand-foot syndrome (22%). Nineteen patients had serial EBV DNA data. Fourteen patients had plasma EBV DNA clearance (turn to 0), and 5 (36%) of these 14 patients had disease recurrence or death, whereas all 5 patients without EBV DNA clearance had disease recurrence or death (3-year DFS: 64.3% vs 0%; P = .001).The use of antiangiogenic agents shortly after radiation therapy might increase the risk of necrosis. This approach needs to be avoided until translational and preclinical studies reveal the underlying mechanism of interaction between radiation therapy and antiangiogenic agents.
- Published
- 2022
48. Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma-Reply
- Author
-
Ji-Bin Li, Zhuo-Chen Lin, and Jian-Hua Fu
- Subjects
Esophagectomy ,Treatment Outcome ,Esophageal Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Surgery ,Chemoradiotherapy ,Esophageal Squamous Cell Carcinoma ,Neoadjuvant Therapy - Published
- 2022
49. Investigation of LO-Coupled Noise for a Sideband Separation Superconducting SIS Receiver
- Author
-
Zhen-Qiang Li, Hai-Long Zhang, Feng-Juan Jin, Ye Xu, Ji-Bin Li, Xu-Guo Zhang, and Ying-Xi Zuo
- Subjects
Physics ,Noise temperature ,Signal generator ,Sideband ,Local oscillator ,Acoustics ,Astronomy and Astrophysics ,Filter (signal processing) ,law.invention ,Telescope ,Space and Planetary Science ,law ,Sensitivity (electronics) ,Noise (radio) - Abstract
The Superconducting Superconductor-Insulator-Superconductor (SIS) receivers have become the preferred method for (sub)millimeter-wave radio astronomical observations due to the extremely low receiver noise temperature. The coupling noise of the local oscillator (LO) system is also a part of the receiver noise. In many years of astronomical observations, it is found that the LO-coupled noise cannot be completely ignored, which has a certain impact on the sensitivity of astronomical observations. The noise temperature of the superconducting SIS receiver was tested using two different kinds of signal generators as the primary signal source of the LO system. It is found that the base noise output by the signal generator can be coupled into the receiver to increase the receiver noise. By adding a narrow band filter to the output of the signal generator, the base noise of the signal generator can be filtered out, and this part noise of the receiver can be eliminated, the overall noise of the receiver is reduced, and the sensitivity of the telescope is improved.
- Published
- 2020
50. Hyperchaos in RTD-Based Cellular Neural Networks.
- Author
-
Feng-Juan Chen and Ji-Bin Li 0001
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.